Patentex Oval N (Suppositories) Instructions for Use
Marketing Authorization Holder
Merz Pharma, GmbH & Co. KGaA (Germany)
ATC Code
G02BB (Intravaginal contraceptives)
Active Substance
Nonoxinol (Rec.INN registered by WHO)
Dosage Form
| Patentex Oval N | Vaginal suppositories 75 mg: 3, 6, or 12 pcs. |
Dosage Form, Packaging, and Composition
Vaginal suppositories white, cylindrical, on a longitudinal section without inclusions, the presence of an air core or a funnel-shaped depression is allowed.
| 1 supp. | |
| Nonoxinol-9 | 75 mg |
Excipients: polyethylene glycol (macrogol) 1500, polyethylene glycol (macrogol) 1000, tartaric acid, sodium bicarbonate, sodium lauryl sulfate.
3 pcs. – blisters (1) – carton packs.
6 pcs. – blisters (1) – carton packs.
6 pcs. – blisters (2) – carton packs.
Clinical-Pharmacological Group
Vaginal contraceptive with spermicidal action
Pharmacotherapeutic Group
Contraceptive agent for topical application
Pharmacological Action
Vaginal contraceptive with spermicidal action.
Patentex Oval N suppositories melt at body temperature and, regardless of the amount of vaginal secretion, form a foam.
The drug reduces the surface tension of the lipid membrane of spermatozoa and irreversibly paralyzes their ability to move.
The drug has a mechanical action, because the spermicidal substance, evenly distributed in the vagina, forms a stable barrier that prevents the penetration of spermatozoa into the uterus.
Patentex Oval N has a preventive effect against sexually transmitted infections.
Pharmacokinetics
Data on the pharmacokinetics of Patentex Oval N are not provided.
Indications
Contraception
- For episodic protection against pregnancy (including with irregular sexual activity);
- With an irregular menstrual cycle;
- When a woman wishes to use a contraceptive independently of her partner;
- When it is necessary to stop (for a short or long time) the use of oral hormonal contraceptives;
- With the simultaneous use of drugs that reduce the effectiveness of oral hormonal contraceptives;
- In the presence of contraindications to the use of oral contraceptives or to the use of intrauterine contraception.
ICD codes
| ICD-10 code | Indication |
| Z30.0 | General advice and consultation on contraception |
| ICD-11 code | Indication |
| QA21.1 | Encounter for general counseling and advice on contraception |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
A mandatory condition for the effectiveness of Patentex Oval N is its correct application.
Before use, the suppository is removed from the blister at the marked place. Before each sexual intercourse, the suppository is inserted deep into the vagina. The drug becomes active 10 minutes after insertion. During this time, the active spermicidal substance is evenly distributed throughout the vagina and forms a stable barrier that prevents the passage of spermatozoa into the uterus.
In case of prolonged sexual intercourse (more than 1 hour), repeated administration of another suppository is necessary.
Before each new sexual intercourse, repeated administration of a suppository is necessary, even in cases where the time interval between two sexual acts is less than 1 hour.
Patentex Oval N can be used for a long period of time.
Adverse Reactions
The drug is well tolerated by both partners. In rare cases, a feeling of warmth may occur. If the vaginal microflora is disturbed, a sensation of itching and burning in the vagina (or penis) may occur.
Contraindications
- Developmental anomalies of the genital organs;
- Cervical erosion;
- Hypersensitivity to the components of the drug.
Use in Pregnancy and Lactation
Data on the safety and efficacy of the drug during lactation (breastfeeding) are not provided.
Overdose
To date, no cases of overdose with Patentex Oval N have been reported.
Drug Interactions
Patentex Oval N is practically not subject to systemic absorption, so interaction with other drugs is unlikely.
Storage Conditions
The drug should be stored out of the reach of children at a temperature not exceeding 25°C (77°F).
Shelf Life
Shelf life – 2.5 years. The drug should not be used after the expiration date printed on the packaging.
Dispensing Status
The drug is available without a prescription.
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer